Symptomtext
patient was administered ACTHIB that was not reconstituted with the supplied diluent and another diluent was used to reconstitute the vaccine with no reported adverse event; Initial information received on 29-Jul-2022 regarding an unsolicited valid non-serious case received from a other health professional. This case involves a patient of unknown demographics, and the patient was administered acthib (HIB (PRP/T) VACCINE) that was not reconstituted with the supplied diluent and another diluent was used to reconstitute the vaccine with no reported adverse event. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. On an unknown date, the patient received an unknown dose of suspect HIB (PRP/T) VACCINE (formulation, strength, route: unknown) lot UJ600AA, expiration date: 30-Nov-2022, in unknown administration site as Immunization. On an unknown date the patient was administered acthib that was not reconstituted with the supplied diluent and another diluent was used to reconstitute the vaccine with no reported adverse event (incorrect product formulation administered) (unknown latency) following the administration of HIB (PRP/T) VACCINE. The patient was administered ACTHIB that was reconstituted with another diluent other than the supplied 0.4% Sodium Chloride ACTHIB diluent. Caller stated that she was doing inventory and there was an extra diluent left in the box, so she thinks that someone must have used another diluent to reconstitute the ACTHIB. She was not sure which alternative diluent was used and did not know which patient received the vaccine. This situation was reported as a medication error due to a patient being administered ACTHIB that was not reconstituted with the supplied diluent and another diluent was used to reconstitute the vaccine. Action taken was not applicable. It was not reported if the patient received a corrective treatment for the event. At time of reporting, the outcome was Unknown for the event. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the guidelines. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.